Creative medical technology holdings secures fda clearance for expanded dose escalation in the clinical trial of celz-201-ddt for chronic lower back pain

Positive interim blinded data supports advancement toward potential pivotal phase 3 study positive interim blinded data supports advancement toward potential pivotal phase 3 study

CELZ Ratings Summary

CELZ Quant Ranking